Luminex Molecular Diagnostics Inc recalls NxTAG Respiratory Pathogen Panel +SARS-CoV-2
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Respiratory pathogen panel may report an elevated rate (7.6% predicted probability of occurrence) of non-specific hMPV target (human Metapneumovirus) results, risk identified predominantly in clinical samples that present positivity for another target, leading to an erroneous co-infection result, can potentially result in hMPV false positives.
- Products
-
- NxTAG Respiratory Pathogen Panel +SARS-CoV-2
- Where it was sold
-
U Nationwide distribution in the states of OH, CA, NC, WI, TN, TX, MI, NY, MO, FL, MA, NJ, PA, VA, AZ, IL, OK, CO, MN.
States: Arizona, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri, North Carolina, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Virginia, Wisconsin
- Units affected
- 613
- About this recall
- NxTAG Respiratory Pathogen Panel +SARS-CoV-2, REF: I056C0468